Despite Eli Lilly’s assurances about an ample supply of its new weight loss drug Zepbound, the company is now facing widespread shortages just months after its approval. While the drugmaker is working to resolve the issue, a quick fix is unlikely, it says, with no immediate end to the shortage in sight. The Food and Drug Administration approved Zepbound in November, introducing a new competitor to Novo Nordisk’s blockbuster weight loss drug Wegovy.
Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina, said that patients who miss more than two weeks of a weight loss drug may be forced to start their treatment over again at the lowest dose and then gradually increase over several weeks, in order to reacclimate to the side effects. Starting over can be “immensely disruptive” and “demoralizing” for patients who have successfully lost weight on the drugs, he said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Source: CNBC - 🏆 12. / 72 Read more »
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trialsThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Source: NBCPhiladelphia - 🏆 569. / 51 Read more »
Eli Lilly's weight-loss drug Zepbound could treat sleep apneaAn FDA green light could mean broader insurance coverage and a new treatment for a condition affecting 20 million Americans.
Source: axios - 🏆 302. / 63 Read more »
Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA saysMost doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S. Food and Drug Administration's website showed on Wednesday.
Source: Reuters - 🏆 2. / 97 Read more »
Eli Lilly Warns That 2 Insulin Products Will Be in Short SupplyDrugmaker Eli Lilly & Co is announcing a temporary shortage of two of its insulin products.
Source: MedicineNet - 🏆 575. / 51 Read more »